Objectives: To assess cost effectiveness of abatacept versus adalimumab, each administered with methotrexate, in treating patients with rheumatoid arthritis (RA) stratified according to baseline anticitrullinated protein antibody (ACPA) levels (marker of poor prognosis in RA). Methods: A payer-perspective cost-effectiveness model simulated disease progression in patients with RA who had previously failed conventional disease-modifying antirheumatic drugs and were starting biologic therapy. Patients commenced treatment with abatacept or adalimumab plus methotrexate and were evaluated after 6 months. Therapy continuation was based on the European League Against Rheumatism treatment response; disease progression was based on the Health Assessment Questionnaire Disability Index score. These score changes were used to estimate health state utilities and direct medical costs. Quality-adjusted life-years (QALYs) and incremental cost per QALY gained were calculated by baseline ACPA groups (Q1, 28–234 AU/ml; Q2, 235–609 AU/ml; Q3, 613–1045 AU/ml; and Q4, 1060–4894 AU/ml). Scenario analysis and one-way and probabilistic sensitivity analyses were used to evaluate robustness of model assumptions. Results: Abatacept resulted in QALY gain versus adalimumab in ACPA Q1, Q3, and Q4; between-treatment difference (difference: Q1, 0.115 Q2, 0.009 Q3, 0.045; and Q4, 0.279). Total lifetime discounted cost was higher for abatacept versus adalimumab in most quartiles (Q2, £77,612 vs. £77,546; Q3, £74,441 vs. £73,263; and Q4, £78,428 vs. £76,696) because of longer time on treatment. Incremental cost per QALY for abatacept (vs. adalimumab) was the lowest in the high ACPA titer group (Q4, £6200/QALY), followed by the next lowest titer group (Q3, £26,272/QALY). Conclusions: Abatacept is a cost effective alternative to adalimumab in patients with RA with high ACPA levels

Additional Metadata
Keywords abatacept, ACPA, adalimumab, cost effectiveness, economic model, ICER, QALY, rheumatoid arthritis, treatment costs.
Persistent URL dx.doi.org/10.1016/j.jval.2017.05.020, hdl.handle.net/1765/116483
Journal Value in Health
Citation
Alemao, E, Johal, S., Al, M.J, & Rutten-van Mölken, M.P.M.H. (2018). Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. Value in Health, 21(2), 193–202. doi:10.1016/j.jval.2017.05.020